GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Regulatory Peptides

• Publication date

  2002-07-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0167-0115(02)00095-2PMID 12137975
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist.

  2002cited by this paper
• Glucagon-like Peptide (GLP)-2 Action in the Murine Central Nervous System Is Enhanced by Elimination of GLP-1 Receptor Signaling*

  2001cited by this paper
• Structure, measurement, and secretion of human glucagon-like peptide-2.

  2000cited by this paper
• The glucagon-like peptides.

  1999cited by this paper
• GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans.

  1999cited by this paper
• Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2.

  1999cited by this paper
• Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.

  1999cited by this paper
• Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2.

  1999cited by this paper
• Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

  1999cited by this paper
• Glucagon-like peptide-1: a potent regulator of food intake in humans

  1999cited by this paper
• Glucagon-like Peptide-1 Retards Gastric Emptying and Small Bowel Transit in the Rat (Effect Mediated Through Central or Enteric Nervous Mechanisms)

  1998cited by this paper
• Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.

  1998cited by this paper
• Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin.

  1998cited by this paper
• Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

  1998cited by this paper
• Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs.

  1998cited by this paper
• Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms.

  1997cited by this paper
• Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms.

  1997cited by this paper
• Enteroglucagon.

  1997cited by this paper
• The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation.

  1997cited by this paper
• Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

  1997cited by this paper
• Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.

  1996cited by this paper
• Induction of intestinal epithelial proliferation by glucagon-like peptide 2.

  1996cited by this paper
• Characteristics of fasting and fed myoelectric activity in rat small intestine: evaluation by computer analysis.

  1996cited by this paper
• A role for glucagon-like peptide-1 in the central regulation of feeding

  1996cited by this paper
• Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans

  1994cited by this paper
• A role for GLP-1(7-36)NH2 in the central control of feeding behaviour

  1993cited by this paper
• Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man

  1993cited by this paper
• Cloning and functional expression of a human glucagon-like peptide-1 receptor.

  1993cited by this paper
• Computer program MMC' to summarize characteristics of activity fronts of migrating myoelectric complex in rat small intestine

  1993cited by this paper
• Characterization of high‐affinity receptors for truncated glucagon‐like peptide‐1 in rat gastric glands

  1990cited by this paper
• Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas.

  1986cited by this paper
• rapid communication Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2

  year unknowncited by this paper

• The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database

  2024cites this paper
• In vitro cell cultures of Brunner's glands from male mouse to study GLP-1 receptor function.

  2022cites this paper
• Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes

  2021cites this paper
• Nutritional and pharmacological strategy in children with short bowel syndrome

  2021cites this paper
• Insights into incretin-based therapies for treatment of diabetic dyslipidemia.

  2020cites this paper
• Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial

  2020cites this paper
• Glucagon-like peptide 1 (GLP-1)

  2019cites this paper
• Glucagon-like Peptide-2 and the Regulation of Intestinal Growth and Function.

  2018cites this paper
• Glucagon-Like Peptide-1 Inhibits Prandial Gastrointestinal Motility Through Myenteric Neuronal Mechanisms in Humans

  2018influential citation
• Short‐chain fatty acids augment rat duodenal mucosal barrier function

  2017cites this paper
• Gastrointestinal and Cardiovascular Effects of Incretin-Based Therapies: Friend or Foe?

  2017cites this paper
• Gastrointestinal actions of glucagon‐like peptide‐1‐based therapies: glycaemic control beyond the pancreas

  2016cites this paper
• GASTRIC EMPTYING AND ADMINISTRATION OF ENTERAL NUTRITION

  2016cites this paper
• CHAPTER SEVEN The role of gastrointestinal hormones in the treatment of delayed gastric emptying in critically ill patients

  2016cites this paper
• Intestinal and neuronal myenteric adaptations in the small intestine induced by a high-fat diet in mice

  2015cites this paper
• Role of Melatonin, Neuropeptide S and Short Chain Fatty Acids in Regulation of Duodenal Mucosal Barrier Function and Motility

  2015cites this paper
• Role of Melatonin, Neuropeptide S and Short Chain Fatty Acids in Regulation of Duodenal Mucosal Barrier Function and Motility

  2015cites this paper
• Effects of centrally injected glucagon-like peptide-2 on gastric mucosal blood flow in rats: possible mechanisms.

  2015cites this paper
• Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle.

  2014cites this paper
• Dipeptidyl Peptidase IV Inhibition Prevents the Formation and Promotes the Healing of Indomethacin-Induced Intestinal Ulcers in Rats

  2014cites this paper
• Glucagon-like peptides 1 and 2 in health and disease: a review.

  2013cites this paper
• Role of glucagon-like peptide-1 in the pathogenesis of experimental irritable bowel syndrome rat models.

  2013cites this paper
• Review article: the role of gastrointestinal hormones in the treatment of delayed gastric emptying in critically ill patients

  2013cites this paper
• Role of glucagon-like peptide–2 deficiency in neonatal short-bowel syndrome using neonatal piglets

  2013cites this paper
• The Acute Regulation of Intestinal Chylomicron Secretion by Glucagon-like Peptides

  2012cites this paper
• Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function

  2011cites this paper
• PCSK2-null mice exhibit delayed intestinal motility, reduced refeeding response and altered plasma levels of several regulatory peptides.

  2011cites this paper
• Gastric relaxation induced by glucagon-like peptide-2 in mice fed a high-fat diet or fasted.

  2011cites this paper
• Glucagon-Like Peptide-1 and Diabetes

  2011influential citation
• The Effect of Glucagon-like Peptide-2 on Insulin-like Growth Factor-1 in Murine Intestinal Subepithelial Myofibroblasts

  2010cites this paper
• Gastric acid secretion and gut peptides: mechanisms involved in inflammatory response

  2010cites this paper
• Role of cholinergic neurons in the motor effects of glucagon-like peptide-2 in mouse colon.

  2010cites this paper
• Peripheral motor action of glucagon‐like peptide‐1 through enteric neuronal receptors

  2010cites this paper
• Motility of the Small Intestine and Colon

  2009cites this paper
• Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36.

  2009cites this paper
• Glucagon-like peptide-2 relaxes mouse stomach through vasoactive intestinal peptide release.

  2009cites this paper
• Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2: Effects on Intestinal Morphology and Absorption, Renal Function, Bone and Body Composition, and Muscle Function

  2009cites this paper
• Receptor‐mediated activation of gastric vagal afferents by glucagon‐like peptide‐1 in the rat

  2009cites this paper
• Functional Ontogeny of the Proglucagon-Derived Peptide Axis in the Premature Human Neonate

  2008cites this paper
• Role of glial cell-line derived neurotropic factor family receptor alpha2 in the actions of the glucagon-like peptides on the murine intestine.

  2007cites this paper
• Role of phosphatidylinositol-3 kinase-gamma in the actions of glucagon-like peptide-2 on the murine small intestine.

  2007cites this paper
• Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes.

  2007cites this paper
• The Glucagon‐Like Peptides

  2006cites this paper
• Glucagon-like Peptide-2 Induces a Specific Pattern of Adaptation in Remnant Jejunum

  2006cites this paper
• Glucagon-like Peptide-2.

  2006cites this paper
• Serum glucagon‐like peptide‐2 levels in neonates: Comparison between extremely low‐birthweight infants and normal‐term infants

  2006cites this paper
• Contraction induced by glicentin on smooth muscle cells from the human colon is abolished by exendin (9–39)

  2005cites this paper
• Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome.

  2005cites this paper
• Oxyntomodulin and glicentin are potent inhibitors of the fed motility pattern in small intestine

  2004cites this paper
• Molecular and cellular biology of small intestinal differentiation, gene expression and hormonal responses.

  2003cites this paper
• Role of Phosphatidylinositol-3 Kinase in the Actions of Glucagon-like Peptide-2 on the Murine Small Intestine Departments of 1 Physiology and 2 Medicine and The

  year unknowncites this paper
• lucagon-Like Peptide-2 Increases Intestinal Lipid Absorption and hylomicron Production via CD 36

  year unknowncites this paper